Cullinan Therapeutics, Inc.

What they do

Cullinan develops first- or best-in-class T cell engagers for autoimmune diseases and oncology. Its immunology pipeline includes CLN-978 (CD19xCD3) for SLE, RA, and Sjögren's disease, and velinotamig (BCMAxCD3) for autoimmune diseases. Its oncology pipeline includes CLN-049 (FLT3xCD3) for AML/MDS and zipalertinib, an EGFR inhibitor partnered with Taiho. The company generates no product revenue and relies on partnerships and funding to advance clinical trials.

Revenue drivers

• Zipalertinib collaboration with Taiho — Potential milestone and royalty payments from Taiho's development and commercialization of zipalertinib, an EGFR ex20ins inhibitor; no revenue recorded in recent years.
• Velinotamig license from Genrix — In-licensed BCMAxCD3 T cell engager; no revenue yet, with Genrix conducting a Phase 1/2 trial in China and Cullinan planning global trials.
• No product revenue — All pipeline products are investigational, and the company reported $0 revenue in 2020, 2022, and all quarters of 2022.

Recent performance

For Q2 2026, Cullinan reported cash and investments of $356 million, with a cash runway into 2029. The company had total assets of $363.8 million, liabilities of $42.0 million, and shareholder equity of $321.8 million as of June 30, 2026. Net losses widened from $167.6 million in 2024 to $219.9 million in 2025, and operating cash flow was negative $175.8 million in 2025. The company has no revenue and continues to incur significant R&D expenses to advance its pipeline.

Strategy

Cullinan is focusing on autoimmune diseases with its CD19 and BCMA T cell engagers, aiming for 'immune reset' and disease modification. It plans to expand CLN-978 into Phase 2 studies in SLE and RA by early 2027, and to initiate a global Phase 1/2 basket study for velinotamig in autoimmune cytopenias. In oncology, it is advancing CLN-049 toward a potentially registrational Phase 2 trial in relapsed/refractory AML, with a combination study planned. The company is also supporting Taiho's regulatory submissions for zipalertinib. Management emphasizes rapid advancement to late-stage development and multiple upcoming data catalysts.

Risks

• Clinical and regulatory risk — All pipeline products are in early-stage trials with no approved products; failures or delays in Phase 1/2 studies could halt development.
• Cash burn and dilution risk — The company has no revenue and continues to generate significant net losses, requiring future capital raises that may dilute shareholders.
• Dependence on partners — Zipalertinib development is largely controlled by Taiho, and velinotamig's early data comes from Genrix, leaving outcomes outside Cullinan's control.
• Competition and market adoption — T cell engagers face competition from other therapies in autoimmune diseases and oncology, and the products may not achieve commercial success if approved.

Outlook

Management expects initial multi-dose data for CLN-978 in RA in Q3 2026 and SLE in Q4 2026, with Phase 2 expansion starting early 2027. Velinotamig multi-dose data in SLE is expected in Q4 2026, and a Phase 1/2 basket study in autoimmune cytopenias is planned for early 2027. CLN-049's potentially registrational Phase 2 study is slated to begin in Q3 2026, with a combination trial later in 2026. Zipalertinib's NDA has an FDA action date of February 27, 2027.